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Extracellular signal-regulated kinase is an MAPK that is most closely associated
with cell proliferation, and the MEK ⁄ ERK signaling pathway is implicated in vari-
ous human cancers. Although epidermal growth factor receptor, KRAS, and BRAF
are considered major targets for colon cancer treatment, the precise roles of the
MEK ⁄ ERK pathway, one of their major downstream effectors, during colon cancer
development remain to be determined. Using ApcD716 mice, a mouse model of
familial adenomatous polyposis and early-stage sporadic colon cancer formation,
we show that MEK ⁄ ERK signaling is activated not only in adenoma epithelial
cells, but also in tumor stromal cells including fibroblasts and vascular endothelial
cells. Eight-week treatment of ApcD716 mice with trametinib, a small-molecule
MEK inhibitor, significantly reduced the number of polyps in the large size class,
accompanied by reduced angiogenesis and tumor cell proliferation. Trametinib
treatment reduced the COX-2 level in ApcD716 tumors in vivo and in primary cul-
ture of intestinal fibroblasts in vitro. Antibody array analysis revealed that tra-
metinib and the COX-2 inhibitor rofecoxib both reduced the level of CCL2, a
chemokine known to be essential for the growth of Apc mutant polyps, in intes-
tinal fibroblasts in vitro. Consistently, trametinib treatment reduced the Ccl2
mRNA level in ApcD716 tumors in vivo. These results suggest that MEK ⁄ ERK sig-
naling plays key roles in intestinal adenoma formation in ApcD716 mice, at least in
part, through COX-2 induction in tumor stromal cells.
C olorectal cancer is one of the leading causes of cancer-related deaths, and its progression is considered to
involve various genetic and epigenetic changes.
Heterozygous Apc mutant mice develop adenomatous polyps
in the intestines, and are widely used as a genetically-engi-
neered model of familial adenomatous polyposis and early-
stage sporadic colon cancer.(1) Loss of heterozygosity at Apc
loci in intestinal epithelial cells of the Apc mutant mice leads
to Wnt signaling activation, resulting in tumor initiation in the
intestines.(2) However, activation of Wnt signaling is not suffi-
cient for tumor formation; we and others reported earlier that
the growth of intestinal tumors in Apc mutant mice required
induction of COX-2 in tumor stromal cells and activation of
mammalian target of rapamycin complex 1 (mTORC1) in
tumor epithelial cells.(3–7) We subsequently found that JNK
activation in adenoma epithelial cells of Apc mutants was
responsible for mTORC1 activation and hence tumor forma-
tion.(8)
The MAPK family consists of ERK, JNK, and p38 MAPK,
and ERK is most closely implicated in the regulation of cell
proliferation and survival, as well as in oncogenic transforma-
tion.(9,10) In colorectal cancer, epidermal growth factor recep-
tor, KRAS, and BRAF are considered major targets for
therapy, and MEK ⁄ERK is one of their important downstream
effectors. However, the roles of the MEK ⁄ERK signaling in
the formation of intestinal adenomas prior to the acquisition of
KRAS or BRAF mutations are not fully understood.
Trametinib is an allosteric inhibitor of MEK1 ⁄2,(11,12) and
has been approved by the FDA for treating patients with meta-
static melanoma harboring the BRAFV600E/K mutation.(9,10)
Here we show that treatment with trametinib suppresses the
growth of intestinal polyps in ApcD716 mice. Activation of
ERK was observed not only in a subset of adenoma epithelial
cells, but also in stromal cells including fibroblasts and vascu-
lar endothelial cells, and trametinib treatment reduced the lev-
els of COX-2 in tumors in vivo and intestinal fibroblasts
in vitro, suggesting a role for stromal MEK ⁄ERK signaling in
intestinal tumor formation.
Materials and Methods
Animals and drug treatments. The construction of ApcD716
mice was described previously.(2) Male and female ApcD716
mice at 10 weeks of age were gavaged with trametinib
(2 mg ⁄kg ⁄day; LC Laboratories, Woburn, MA, USA) or vehi-
cle (2% acetic acid, 10% polyoxyethylene(10) castor oil, and
10% PEG400) for 8 weeks.(12)
All animal experiments were carried out according to the
protocols approved by the Animal Care and Use Committee of
Aichi Cancer Center Research Institute (Nagoya, Japan).
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Microvessel density. Microvessel density was determined as
described previously.(5)
Western blot analysis. Western blot analysis was carried out
as described previously,(5) using primary antibodies for b-actin
(Sigma-Aldrich, St. Louis, MO), phosphorylated p-S6, p-Akt,
p-ERK1 ⁄2, p-JNK, p-p38, p-STAT3, COX-1 (Cell Signaling
Technology, Danvers, MA, USA), and COX-2 (Cayman
Chemical, Ann Arbor, MI, USA).
Angiogenesis antibody array analysis. Primary mouse intesti-





Fig. 1. Activation of ERK in intestines of WT and ApcD716 mice. (a) Western blot analysis for ERK phosphorylation in various parts of the intes-
tines of WT C57BL ⁄ 6 mice treated with trametinib or vehicle (control). Col, colon; Duo, duodenum; Ile, Ileum; Jej, jejunum. (b) Immunostaining
of p-ERK in intestines of WT mouse treated with trametinib or vehicle (control) for 1 week. Lower panels of each section show higher magnifica-
tion of the boxed areas in the corresponding upper panels. Bar = 50 lm. (c) Western blot analysis for effects of trametinib treatment on signal-
ing pathways in the ileum of WT mouse. (d) Western blot analysis for effects of trametinib treatment on signaling pathways in normal intestinal
mucosa (N) and polyps (P) of ApcD716 mouse. (e) Immunostaining of p-ERK in intestinal polyps of ApcD716 mouse treated with trametinib or vehi-
cle (control) for 1 week. Lower panels show higher magnifications of the boxed areas in the upper panels. Bars, upper panels = 200 lm; lower
panels = 50 lm.
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then cultured in DMEM with 10% FBS in the presence of tra-
metinib (10 nM), rofecoxib (10 lM; Sigma), or vehicle control
(DMSO) for 16 h. Preparation of whole cell lysates and anti-
body array analysis was carried out according to the manufac-
turer’s protocol (Mouse Angiogenesis Array Kit, ARY015;
R&D Systems, Minneapolis, MN).
Statistical analysis. Statistical analyses were carried out using
R (version 3.0.2; R Foundation for Statistical Computing,
Vienna, Austria) with the EZR package (version 1.20; Saitama
Medical Center, Jichi Medical University, Saitama, Japan).(13)
Values of P < 0.05 were considered significant.
Details on histological analysis and immunohistochemistry,
immunofluorescence analysis, BrdU staining, RT-PCR analy-
sis, and primary culture of intestinal fibroblasts are provided in
Data S1.
Results
Activation status of ERK in normal intestines and intestinal pol-
yps of ApcD716 mice. To study the roles of MEK ⁄ERK signaling
in intestinal polyp formation, we first determined the ERK
activation status in normal intestines of WT C57BL ⁄6 mice
and intestinal adenomatous polyps in ApcD716 mice. Western
blot analysis with a p-ERK antibody showed ERK activation
in the intestines of WT mice, with weaker activation in the
colon compared with the small intestine (Fig. 1a). Immunohis-
tochemical analysis showed marked ERK phosphorylation in
intestinal epithelial cells of the crypts, which was stronger in
the proximal parts of the small intestine, namely the duodenum
and jejunum, as compared with the ileum and colon (Fig. 1b).
The ERK phosphorylation levels in intestinal stromal cells did
not differ significantly in the proximal–distal axis of the intes-
tines. One-week treatment of the WT mice with the MEK
inhibitor trametinib greatly reduced the phosphorylation levels
of ERK, but not those of JNK, p38 MAPK, STAT3, Akt, or
S6, suggesting efficient and specific inhibition of the MEK
⁄ERK pathway in the intestines by trametinib with minimal
effects on the JNK, p38 MAPK, JAK–STAT, PI3K–Akt, or
mTOR pathways (Fig. 1a–c). Western blot analysis using sam-
ples from 10-week old ApcD716 mice showed similar levels of
ERK phosphorylation between the normal intestinal mucosa
and intestinal tumors (Fig. 1d). JNK signaling was activated in
the tumors, whereas PI3K and p38 MAPK pathways were not,
as we reported previously.(8) Although ERK phosphorylation
was observed in tumor epithelial cells near the luminal side, it
was more prominent in tumor stromal cells (Fig. 1e). One-
week treatment of ApcD716 mice with trametinib significantly
reduced the ERK phosphorylation level in the polyps (Fig. 1d,
e). Trametinib treatment induced a mild increase in the p38
MAPK phosphorylation level in the polyps; the molecular
mechanisms and biological significance underlying this obser-
vation are currently unknown.
To identify stromal cell types that showed MEK ⁄ERK acti-
vation in the intestinal polyps of ApcD716 mice, we next carried
Fig. 2. Co-immunostaining analyses for p-ERK and
markers of stromal cells. Immunofluorescence
staining for p-ERK and vimentin (left panels,
mesenchymal cell marker), CD34 (middle panels,
vascular endothelial cell marker), and a-smooth
muscle actin (a-SMA) (right panels, a myofibroblast
marker) in small intestinal polyps of ApcD716 mice
using confocal laser scanning microscopy (964).
Nuclei are stained with DAPI (blue). Top panels
show merged images with p-ERK in green, stromal
cell markers in red, and DAPI in blue. Arrows
indicate cells that are double-positive for p-ERK and
stromal cell markers.
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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out co-immunostaining with the p-ERK antibody and antibod-
ies against markers of some stromal cell types, specifically vi-
mentin (a mesenchymal cell marker), CD34 (a vascular
endothelial cell marker), a-smooth muscle actin (a-SMA; a
myofibroblast marker), b-tubulin III (a neuronal cell marker),
lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1;
a lymphatic endothelial cell marker), and CD45 (a leucocyte
marker) (Figs 2,S1,S2). Although only a small fraction (<10%)
of vimentin, CD34, or a-SMA positive cells showed co-stain-
ing for p-ERK in the normal intestinal mucosa (Fig. S1), a
good percentage (>60%) of them showed co-staining in the
polyps, especially in their luminal side (Figs 2,S1). The cells
co-stained with both vimentin and p-ERK showed spindle-
shaped morphology and their frequency was much higher than
that of other specified stromal cells, which suggest that those
cells are likely fibroblasts, although they are difficult to posi-
tively identify due to the lack of specific marker antibodies.
We observed some stromal cells co-stained for p-ERK with b-
tubulin III or LYVE-1. However, the frequency of b-tubulin
III-positive or LYVE-1-positive cells was extremely low in the
polyps (<10 per polyp section, as compared with >100 for vi-
mentin-positive cells) and their significance is thus unknown
(Figs S1,S2). Co-staining for p-ERK and CD45 was rarely
observed in the polyps (Figs S1,S2). These results suggest that
p-ERK-positive stromal cells in the ApcD716 polyps mainly
include vascular endothelial cells, myofibroblasts, and probably
fibroblasts.
Trametinib treatment inhibits polyp formation in ApcD716 mice.
To determine whether MEK ⁄ERK signaling was involved in
intestinal tumor formation, we then treated ApcD716 mice with
trametinib for 8 weeks from 10 to 18 weeks of age (Fig. 3a).
As shown in Figure 3(b,c), trametinib treatment significantly
reduced the number of intestinal polyps in the large size class
(Φ ≥ 1.5 mm). Polyps in trametinib-treated ApcD716 mice
showed a collapsed morphology at the top (Fig. 3d), similarly
to the polyps of ApcD716 mice in which COX-2 or mTORC1
was inhibited.(3,5,8)
To study the mechanism of inhibition of polyp formation by
trametinib, we next evaluated cell proliferation rate by BrdU
incorporation assay. Treatment with trametinib significantly
reduced the BrdU labeling index of adenoma epithelial cells,
whereas no change was observed in that of normal intestinal
epithelial cells (Fig. 4a,b). Activation of ERK in tumor vascu-
lar endothelial cells (Fig. 2) suggests the possibility that MEK
inhibition may affect tumor angiogenesis. We thus examined
the effects of trametinib treatment on angiogenesis in ApcD716
intestinal polyps. Eight-week treatment significantly reduced
the microvessel density in the polyps (Fig. 4c,d). These results
suggest that trametinib treatment may suppress tumor forma-
tion in ApcD716 mice by inhibiting tumor cell proliferation and
angiogenesis.
Trametinib treatment reduces levels of COX-2 and CCL2 in
ApcD716 polyps. Stromal COX-2 has been implicated in intesti-
nal polyp formation in ApcD716 mice through regulation of
angiogenesis.(14) We next determined the effects of trametinib
treatment on COX-2 expression levels. Western blot analysis
showed that expression of COX-2, but not COX-1, was
induced in ApcD716 polyps as reported previously,(3) and that
the COX-2 induction was suppressed dramatically by 1-week
treatment with trametinib (Fig. 5a). Real-time RT-PCR analy-
sis revealed that trametinib significantly decreased the COX-2




Fig. 3. Trametinib treatment suppresses adenoma
formation in ApcD716 mice. (a) Schematic diagram
of the trametinib treatment schedule for ApcD716
mice. (b) Gross appearance of intestinal polyps in
ApcD716 mice treated with vehicle (control) or
trametinib. (c) Number of polyps in the large-size
(Φ ≥ 1.5 mm) and small-size (Φ < 1.5 mm) classes in
ApcD716 mice treated with vehicle (control, n = 5) or
trametinib (n = 6). Data are average  SD, and
statistical significance was assessed by Student’s
t-test. *P < 0.05. (d) H&E staining of adenomatous
polyps in ApcD716 mouse treated with vehicle
(control) or trametinib. Bar = 200 lm.
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of the MEK ⁄ERK signaling in COX-2 expression, we then
examined localization of the COX-2 expressing cells and the
cells positive for p-ERK staining in the polyps. As co-staining
was not possible, we carried out immunohistochemical analysis
using serial sections, which showed a similar staining pattern
for p-ERK and COX-2 (Fig. 5c). Previous studies that showed
the critical role of COX-2 in intestinal polyp formation in
ApcD716 mice identified stromal fibroblasts and vascular endo-
thelial cells as the main cell types that expressed COX-2 in
their tumors.(4) Because intestinal vascular endothelial cells
were difficult to isolate for primary cultures, we examined the
effects of trametinib treatment on COX-2 expression using pri-
mary culture of fibroblasts prepared from the intestines of ~8-
week-old WT mice. Trametinib treatment strongly suppressed
COX-2 induction by serum stimulation at both protein and
mRNA levels (Fig. 5d,e), suggesting the requirement of MEK
⁄ERK signaling for COX-2 expression in intestinal fibroblasts.
To gain insights into the possible mechanisms by which MEK
⁄ERK signaling may contribute to tumor angiogenesis and
tumor growth through COX-2 induction in intestinal fibro-
blasts, we carried out angiogenesis antibody array analysis
using lysates of intestinal fibroblasts treated with rofecoxib or
trametinib. As shown in Figure 5(f), treatment with rofecoxib
or trametinib markedly reduced the level of CCL2 (MCP-1) as
compared with vehicle control. Moreover, the mRNA level of
Ccl2 was markedly elevated in the intestinal polyps of ApcD716
mice, which was greatly reduced by trametinib treatment
(Fig. 5g). Taken together, these results suggest the possibility
that the MEK ⁄ERK signaling positively regulates CCL2
expression through COX-2 induction in intestinal fibroblasts,
which may help to promote angiogenesis and hence the growth
of ApcD716 polyps.
Discussion
In the present study, we have shown that the MEK inhibitor
trametinib suppresses formation of intestinal adenomas in
ApcD716 mice, and propose that the antitumor effect of trameti-
nib is at least in part mediated by its ability to suppress COX-
2 induction in the tumor microenvironment. First, we have
shown ERK activation not only in some tumor epithelial cells,
but also in vascular endothelial cells, myofibroblasts, and vi-
mentin-positive mesenchymal cells (likely fibroblasts) in the
tumor stroma (Figs 1b,c,2,S1,S2). Second, trametinib treatment
greatly reduced the COX-2 levels in ApcD716 polyps in vivo, as
well as in primary culture of fibroblasts prepared from mouse
intestines in vitro (Fig. 5). Our previous studies on ApcD716
mice clarified essential roles of COX-2 induction in intestinal
tumor formation,(3,15,16) and identified fibroblasts and vascular
endothelial cells as major producers of COX-2 in the intestinal
polyps.(4) In this study, we have observed overlapped staining
patterns for p-ERK-positive and COX-2-positive cells in serial
sections of the luminal side of the polyps where most of the
COX-2-expressing cells resided. Consistently, many vascular
endothelial cells and fibroblasts were found in the luminal side
of the polyps (Fig. S1).
Regarding the roles of ERK in intestinal tumor formation
in Apc mutant mice, Lee et al.(17) reported that intestinal mi-
croflora activated ERK in intestinal tumor epithelial cells of
ApcMin mice through MyD88, a key signaling molecule
(a) (b)
(c) (d)
Fig. 4. Trametinib attenuates adenoma cell proliferation and angiogenesis. (a) Micrographs of normal intestinal mucosa and adenoma epithe-
lium labeled with BrdU in ApcD716 mouse treated with vehicle (control) or trametinib for 8 weeks. Bar = 50 lm. (b) BrdU labeling indices of nor-
mal intestinal mucosa and adenoma epithelium in ApcD716 mouse treated with vehicle (control) or trametinib. Data are average  SD, and
statistical significance was assessed by one-way ANOVA and Tukey’s test. *P < 0.05. (c) Immunostaining of CD34 in a small intestinal polyp of vehi-
cle-treated (left) and trametinib-treated (right) ApcD716 mice. Bar = 50 lm. (d) Microvessel density in polyps of vehicle-treated (left) or trameti-
nib-treated (right) ApcD716 mice. Data are average  SD, and statistical significance was assessed by Student’s t-test. **P < 0.01.
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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downstream of Toll-like receptors. They further showed that
the activated ERK phosphorylated and thereby stabilized c-
Myc protein in tumor epithelial cells, leading to promotion of
the tumor growth.(17) In the study they showed suppression
of tumor formation in ApcMin mice by treatment with the
MEK1 inhibitor PD98059, consistent with our finding using
trametinib. Although our present work suggests the roles of
the MEK ⁄ERK signaling in tumor microenvironment, in con-
trast to its direct role in tumor epithelial cells as suggested
by Lee et al., the two proposed mechanisms are not mutually
exclusive and may co-operate in promoting tumor formation.
The upstream signaling that activates ERK also remains to be
clarified. Lee et al.(17) claimed the importance of intestinal
bacteria in activating ERK through MyD88 in intestinal epi-
thelial cells. However, experiments using germ-free mice or
antibiotic treatment showed mixed results as to the roles of
intestinal microflora in tumor formation in Apc mutant
mice,(18–22) with some reports suggesting their limited roles
in tumor formation.
Angiogenesis antibody array analysis identified CCL2 (also
known as MCP-1) as a candidate molecule regulated by both
MEK ⁄ERK signaling and COX-2 in intestinal fibroblasts
(Fig. 5f). CCL2 is a pro-inflammatory chemokine that has been
implicated in monocyte recruitment, angiogenesis, and devel-
opment of tumor microenvironment.(23) Previous studies by
others showed that Ccl2 was highly expressed in the polyps of
ApcMin mice,(24) and that Ccl2 deficiency significantly reduced
the number of intestinal polyps, especially that of large polyps,
in ApcMin mice.(25) We confirmed elevated Ccl2 mRNA levels
in the polyps of ApcD716 mice, which were markedly reduced
by trametinib treatment (Fig. 5g), suggesting the possibility
that the MEK ⁄ERK signaling activation in stromal fibroblasts
may promote tumor angiogenesis in part by positively regulat-
ing COX-2 and CCL2. We also observed co-staining of
p-ERK and vascular endothelial cells in intestinal tumors
(Fig. 2). MEK ⁄ERK signaling has been implicated in angio-
genesis;(26) for instance, the MEK1 inhibitor selumetinib was




Fig. 5. Trametinib treatment reduces COX-2 levels in polyps and stromal fibroblasts of ApcD716 mice. (a) Western blot analysis for COX-2 and
COX-1 in normal intestinal mucosa (N) and polyps (P) of ApcD716 mice treated with vehicle (control) or trametinib for 1 week. (b) Expression of
COX-2 analyzed by real-time RT-PCR in normal intestinal mucosa and polyps of ApcD716 mice treated with vehicle (control) or trametinib for
1 week. Fold changes in expression levels were determined relative to the levels in normal intestinal mucosa of vehicle-treated mice. Data are
average  SD, and statistical significance was assessed by one-way ANOVA and Tukey’s test. *P < 0.05. (c) Immunostaining of p-ERK and COX-2 in
ileal polyps of ApcD716 mouse. Bar = 20 lm. (d) Western blot analysis of COX-2, COX-1, and MAPKs in primary cultures of intestinal fibroblasts
prepared from ~8-week-old WT mice. Serum-starved cells were stimulated with serum in the presence or absence of trametinib (at 2 or 20 nM).
(e) Expression of COX-2 analyzed by real-time RT-PCR in primary cultures of intestinal fibroblasts treated as in (d). Fold changes in expression lev-
els were determined relative to the levels in the cells stimulated with 10% FBS in the absence of trametinib (control). Data are average  SD,
and statistical significance was assessed by one-way ANOVA and Tukey’s test. *P < 0.05. (f) Angiogenesis antibody array analysis of primary intesti-
nal fibroblasts. Serum-starved cells were stimulated with serum in the presence of vehicle control (DMSO), rofecoxib (10 lM), or trametinib
(10 nM). (g) Semiquantitative RT-PCR analysis of Ccl2 expression in normal intestinal mucosa (N) and polyps (P) of ApcD716 mice treated with vehi-
cle (control) or trametinib for 1 week.
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xenografts, accompanied by decreased microvessel density.(27)
The antiangiogenic activity of trametinib could thus be combi-
nation of direct effects on endothelial cells and indirect effects
mediated by reduced expression of COX-2 in fibroblasts.
The mechanisms by which MEK ⁄ERK signaling positively
regulates COX-2 in stromal fibroblasts and vascular endothelial
cells of ApcD716 polyps are currently unknown. Expression of
COX-2 is regulated at the transcriptional and post-transcrip-
tional levels,(28) and ERK has been implicated in both levels
of control in fibroblasts.(29–31) The molecular mechanism of
the MEK ⁄ERK activation in the tumor stroma are also not
clear. Further studies will elucidate the molecular mechanisms
underlying COX-2 induction by MEK ⁄ERK signaling in tumor
stromal fibroblasts.
Trametinib has been approved for treating metastatic mela-
noma patients with BRAFV600E ⁄K mutations.(9,10,32) Studies
on metastatic melanoma patients with BRAFV600E ⁄K muta-
tions showed that combination treatment with the BRAF inhib-
itor dabrafenib and trametinib had better efficacy than single
dabrafenib treatment, and also induced less skin toxicity, with
decreased numbers of patients developing hyperkeratosis or
skin papillomas.(33) A recent report showed that COX-2 inhibi-
tion can prevent the appearance of keratoacanthomas and cuta-
neous squamous cell carcinomas after treatment with BRAF
inhibitors in a mouse model.(34) The beneficial effects of tra-
metinib when combined with BRAF inhibitors thus may, in
part, be through its effect on reducing COX-2 levels. Clinical
trials are underway for treatment of colorectal cancers using
multiple kinase inhibitors including trametinib and dabrafenib
(Clinical-Trials.gov identifiers NCT01750918 and
NCT01902171), in which the ability of trametinib to reduce
COX-2 levels may also be beneficial.
In conclusion, we have shown that MEK ⁄ERK signaling is
activated in some tumor epithelial cells and stromal cells in
the intestinal polyps of ApcD716 mice, and that the MEK inhib-
itor trametinib potently suppresses tumor formation, accompa-
nied by reduced COX-2 induction in the tumor stroma. These
results also suggest that trametinib, a drug that is already
approved for treating a subset of melanoma patients, may be
useful for prevention of colonic polyp formation in familial
adenomatous polyposis patients with APC mutations.
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